XOMA’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $123.00 target price on the biotechnology company’s stock, up from their prior target price of $117.00. HC Wainwright’s price target would indicate a potential upside of 268.26% from the stock’s current price.

Separately, StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

XOMA Stock Performance

XOMA stock traded down $0.05 during midday trading on Monday, hitting $33.40. The company’s stock had a trading volume of 7,801 shares, compared to its average volume of 22,034. The stock has a market cap of $393.55 million, a price-to-earnings ratio of -9.60 and a beta of 0.90. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock’s 50-day moving average price is $29.37 and its 200 day moving average price is $27.37. XOMA has a 1 year low of $14.77 and a 1 year high of $35.00.

Insider Buying and Selling

In other news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.20% of the stock is currently owned by insiders.

Institutional Trading of XOMA

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in XOMA during the 1st quarter worth approximately $212,000. Rhumbline Advisers lifted its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares in the last quarter. Barclays PLC boosted its stake in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares during the period. Finally, Ellsworth Advisors LLC purchased a new stake in XOMA during the 3rd quarter valued at approximately $516,000. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.